Edition:
United States

Heat Biologics Inc (HTBX.OQ)

HTBX.OQ on NASDAQ Stock Exchange Capital Market

2.24USD
20 Jul 2018
Change (% chg)

$-0.07 (-3.03%)
Prev Close
$2.31
Open
$2.31
Day's High
$2.31
Day's Low
$2.23
Volume
37,887
Avg. Vol
244,069
52-wk High
$7.85
52-wk Low
$1.09

Select another date:

Wed, Jun 27 2018

Heat-stable drug could save thousands from post-childbirth bleeding: WHO

LONDON A new formulation of a drug to prevent excessive bleeding in women after they give birth could save thousands of lives in poorer countries, according to a study co-led by the World Health Organization (WHO).

Heat-stable drug could save thousands from post-childbirth bleeding - WHO

LONDON, June 27 A new formulation of a drug to prevent excessive bleeding in women after they give birth could save thousands of lives in poorer countries, according to a study co-led by the World Health Organization (WHO).

BRIEF-Heat Biologics Inc - QTRLY Loss Per Share $0.75

* HEAT BIOLOGICS INC - QTRLY LOSS PER SHARE $0.75 Source text: (https://bit.ly/2rHWu1b) Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Heat Biologics Files For Offering Of Up To $15 Mln Of Its Common Stock

* FILES FOR OFFERING OF UP TO $15 MILLION OF ITS COMMON STOCK - SEC FILING Source text for Eikon: (http://bit.ly/2GFwyfW) Further company coverage:

BRIEF-Heat Biologics Reports Data From Phase 2 Trial Of HS-410 Combined With Bacillus Calmette-Guérin For Treating Non-Muscle Invasive Bladder Cancer

* HEAT BIOLOGICS - REPORTS 2 YEAR DATA FROM PHASE 2 TRIAL OF HS-410 COMBINED WITH BACILLUS CALMETTE-GUÉRIN FOR TREATING NON-MUSCLE INVASIVE BLADDER CANCER

BRIEF-Heat Biologics Files Prospectus Supplement Related To Offering Of Up To $1.3 Million Shares Of Co's Common Stock

* HEAT BIOLOGICS INC FILES PROSPECTUS SUPPLEMENT RELATED TO OFFERING OF UP TO $1.3 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING‍​ Source text (http://bit.ly/2G2V1vx) Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Heat Biologics - Interim Results From Phase 2 Study Investigating HS-110 In Combination With Anti-PD-1

* HEAT BIOLOGICS - INTERIM RESULTS FROM PHASE 2 STUDY INVESTIGATING HS-110 IN COMBINATION WITH BRISTOL-MYERS'S ANTI-PD-1 CHECKPOINT INHIBITOR, NIVOLUMAB

BRIEF-Heat Biologics Gets Recommendation To Continue Patient Enrollment Of Ongoing Phase 2 Clinical Trial

* SAYS GOT INDEPENDENT DMC RECOMMENDATION TO CONTINUE PATIENT ENROLLMENT OF ONGOING PHASE 2 CLINICAL TRIAL FOR HS-110 AND NIVOLUMAB​ Source text: (http://bit.ly/2BG2kXt) Further company coverage:

Select another date: